Health Care

Greenwich Lifesciences expands FLAMINGO‑01 Europe enrollment, gaining EMA approval to combine HLA‑A02:01 and HLA‑A24:02, boosting oncology trial power and investor appeal.

GlucoTrack completes a strategic business combination with Lōkahi Therapeutics, securing bridge financing to fuel growth and AI‑driven healthcare innovation.

Vaxart’s oral flu vaccines target gut immunity, offering a painless, effective alternative to injections—an innovative biotech breakthrough with solid growth prospects.

Explore Satellos Bioscience’s cutting‑edge muscle‑regeneration therapy—Toronto‑based biotech aiming to unlock natural healing for severe muscle disorders.

Merck KGaA unveils a €25 M, 2,000‑sqm BioReliance testing hub in Darmstadt to accelerate GMP‑compliant drug release and stability studies across Europe.

Explore how Eli Lilly’s $3.8 B purchase of AtaiBeckley marks a bold entry into psychedelic medicine, reshaping its portfolio and the neuro‑psychiatric market.

Brainsway’s bullish outlook grows stronger as H.C. Wainwright reaffirms a $14 target and Buy rating, while its stake in Sound Minds Behavioral expands its behavioral‑health reach.

Hyperliquid Strategies (HYPE) drops 10% amid Bitcoin decline, regulatory uncertainty and new crypto‑ETF competition, but institutional backing and upcoming Clarity Act hearing may shape its future.

Option Care Health delivers specialized infusion & home‑care solutions for serious illnesses, boosting patient outcomes nationwide—discover why investors trust its growth.

Orion Oyj’s Q2 beats expectations, driving revenue +25% and margin to 33.9%. The company lifts its 2026 profit outlook, positioning itself as a resilient, growth‑oriented pharma player.